Researchers showed that an RNA-based therapy targeting the SETBP1 mutation reduced the incidence of hydrocephalus in mice, ...
Wave claimed GSK is walking away from the frontrunning program not because of questions about its potential, but because Wave ...
Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive ...
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in ...
Investing.com -- Wave Life Sciences Ltd (NASDAQ:WVE) stock rose 2.1% Monday after the clinical-stage biotechnology company announced it has regained full rights to WVE-006, its investigational RNA ...
Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...
We recently published 10 Shares Explode as Earnings Impress. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Friday. Avidity Biosciences saw its share prices increase by ...
In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results